Simvastatin Prescribing Patterns Before and After FDA Dosing Restrictions: A Retrospective Analysis of a Large Healthcare Claims Database

Conclusions Despite improvements in prescribing practices, many patients are still exposed to potentially harmful simvastatin combinations. Aggressive changes in simvastatin prescribing systems and processes are needed to improve compliance with FDA labeling to improve medication and patient safety.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research